<DOC>
	<DOCNO>NCT00119236</DOCNO>
	<brief_summary>This phase I trial study side effect best dose 17-AAG irinotecan treating patient locally advance metastatic solid tumor . Drugs use chemotherapy , 17-AAG irinotecan , work different way stop growth tumor cell either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell .</brief_summary>
	<brief_title>17-AAG Irinotecan Treating Patients With Locally Advanced Metastatic Solid Tumors</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine maximum tolerate dose ( MTD ) combine 17AAG irinotecan give weekly two week 21-day cycle use future phase II study . SECONDARY OBJECTIVES : I . To explore effect combination expression Hsp90 client proteins peripheral mononuclear cell tumor tissue . Tumor biopsy perform 17AAG treatment 12 patient MTD ( `` Expanded Cohort '' ) . II . To investigate clinical pharmacokinetics intravenous 17AAG , irinotecan , metabolite , combination . III . To obtain preliminary data therapeutic activity 17AAG combination irinotecan patient advance solid tumor . IV . To obtain preliminary result relationship tumor response p53-status . OUTLINE : This open-label , non-randomized , dose-escalation study . Patients receive irinotecan IV 30 minute follow 17-N-allylamino-17-demethoxygeldanamycin ( 17-AAG ) * IV 2 hour day 1 8 . Treatment repeat every 21 day least 2 course absence disease progression unacceptable toxicity . Patients achieve stable improve disease course 2 may receive additional course treatment . NOTE : *17-AAG administered day 2 8 course 2 patient treat non-maximum tolerated dos ( MTD ) ( dose-escalation portion ) day 8 course 1 patient treat MTD ( expand cohort ) .Cohorts 3-6 patient receive escalate dos 17-AAG irinotecan MTD determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . An additional 12 patient treated MTD .</detailed_description>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Histologically confirm solid tumor , exclude primary CNS tumor Locally advance metastatic disease refractory standard therapy OR standard therapy exist Tumor assessible biopsy Trucut^® , CT guidance , endoscopy ( patient treat maximum tolerate dose [ expand cohort ] ) Pleural effusion abdominal ascites consider biopsyaccessible tissue No known new CNS metastases previously treat Performance status Karnofsky 60100 % WBC ≥ 3,000/mm^3 Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Bilirubin ≤ 1.5 mg/dL AST ALT ≤ 3 time upper limit normal ( ULN ) ( 5 time ULN liver metastasis present ) Creatinine ≤ 1.5 mg/dL No history cardiac arrhythmia No myocardial infarction within past 12 month No active ischemic heart disease within past 12 month No New York Heart Association class IIIIV congestive heart failure LVEF &lt; 40 % MUGA No history uncontrolled cardiac dysrhythmia dysrhthmias require medication No history serious ventricular arrhythmia ( i.e. , ventricular tachycardia ventricular fibrillation ≥ 3 beat row ) No congenital long QT syndrome No leave bundle branch block QTc &lt; 450 msec ( male patient ) QTc &lt; 470 msec ( female patient ) Not pregnant No nursing 2 month study participation Negative pregnancy test Fertile patient must use effective contraception 2 month study participation No serious uncontrolled infection No history serious allergic reaction egg egg product No medical condition would preclude study participation At least 3 week since prior immunotherapy No concurrent prophylactic filgrastim ( GCSF ) sargramostim ( GMCSF ) At least 3 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) Prior irinotecan allow No prior 17Nallylamino17demethoxygeldanamycin ( 17AAG ) At least 2 week since prior nonmyelosuppressive chemotherapy ( discretion principal investigator ) At least 3 week since prior radiotherapy No prior radiotherapy field include heart ( e.g. , mantle ) Recovered prior therapy At least 3 week since prior anticancer investigational therapeutic drug More 7 day since prior concurrent inducer , inhibitor , modifier CYP3A4 , include follow : Fluconazole Itraconazole Ketoconazole Azithromycin Clarithromycin Erythromycin Troleandomycin Nifedipine Verapamil Diltiazem Nefazodone Cyclosporine Grapefruit juice ( &gt; 1 quart/day ) Indinavir Nelfinavir Ritonavir Saquinavir Carbamazepine Phenobarbital Phenytoin Rifampin Hydrastis canadensis ( goldenseal ) Hypericum perforatum ( St. John 's wort ) Uncaria tomentosa ( cat 's claw ) Echinacea angustifolia root Trifolium pratense ( wild cherry ) Matricaria chamomila ( chamomile ) Glycyrrhiza glabra ( licorice ) Dillapiol Hypericin Naringenin No concurrent medication would prolong QTc No concurrent vitamin , antioxidant , herbal preparation , supplement Concurrent single daily multivitamin allow No concurrent anticancer therapy No concurrent combination antiretroviral therapy HIVpositive patient No concurrent investigational medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>